<DOC>
	<DOC>NCT01071876</DOC>
	<brief_summary>Multicenter randomized double blind study versus placebo during 12 weeks with at first, an escalating dose period followed by stable dose period at the selected dose. This double-blind period can be followed by a 9 months open-label period if the patient wishes to continue with the study product.</brief_summary>
	<brief_title>BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS</brief_title>
	<detailed_description>The first period (12 weeks double blind period) will aim at demonstrating the efficacy and safety of BF2.649 by verifying whether the results of BF2.649 are superior to those of placebo. The aim of the second period (open label extension phase) will be to assess the long-term tolerance, as well as the maintenance of the BF2.649 efficacy.</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<criteria>patients with OSA treated by nCPAP but still complaining with EDS ESS score &gt; or = 12 patient suffering from insomnia without OSA coexisting narcolepsy patient with sleep debt not due to OSA acute or chronic severe disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Sleep disorder</keyword>
	<keyword>obstructive sleep apnea</keyword>
	<keyword>excessive daytime sleepiness</keyword>
	<keyword>patients with OSA treated by CPAP presenting EDS</keyword>
</DOC>